CRISPR Therapeutics (CRSP) Announces Proposed 4.25M Common Share Offering

CRISPR Therapeutics (NASDAQ: CRSP) today announced that it is commencing an underwritten public offering of 4,250,000 common shares. In addition, the underwriters will have a 30-day option to purchase up to 637,500 additional common shares at the public offering price less the underwriting discount.

Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

You May Also Be Interested In

• InnovAge stockholders price secondary offering of 10M shares at $9.25
• UWM Holdings sets terms for 200 million share rights offering
• Decoy Therapeutics raises $3.85M via warrant inducement deal